China's biotech firms record surge in overseas licensing deals in first quarter
Chinese biotech companies accelerated in the first quarter, with the number of overseas deals surging 18 per cent year on year, showing strong momentum in the field of drugs research, according to a new report.
Advertisement
Chinese drug makers landed 33 deals with overseas healthcare firms in the first three months of this year, with transactions totalling US$36.2 billion, according to a report published on Wednesday by mainland pharmaceutical and biotech consultancy DrugTimes.
That was up from the first quarter last year, when Chinese biotech firms made 28 overseas deals, according to the report. There were 98 transactions recorded in 2024, with a total value of US$59.5 billion.
The largest deal in the first quarter, with a contract value of US$13 billion, was between GeneQuantum – headquartered in Suzhou, a city in eastern Jiangsu province – and Nasdaq-listed Biohaven as well as Seoul-based pharmaceutical firm AimedBio. It involved antibody drug conjugates, which are a class of drugs designed as a targeted therapy for treating cancer.
In one of the deals last quarter, Hong Kong-listed biotech firm Harbour BioMed entered into a strategic global collaboration with AstraZeneca to develop next-generation, multi-specific antibodies for immunology and oncology. The deal was valued at US$4.7 billion, according to DrugTimes.
Advertisement
The steady rise of these deals, including out-licensing and joint ventures, reflects how the Chinese pharmaceutical sector is expanding offshore.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
43 minutes ago
- South China Morning Post
Should Hong Kong's baby bonus scheme include talent to boost birth rate?
Questions have been raised about the effectiveness of potentially extending a baby bonus scheme to talent admitted to Hong Kong to boost the birth rate, despite some professionals complaining about being left out. Advertisement Experts and lawmakers said that other incentives and measures were needed to encourage childbearing and boost the birth rate. Last month, Secretary for Labour and Welfare Chris Sun Yuk-han said the Newborn Baby Bonus Scheme was under review, with authorities to consider suggestions, including whether to extend it to cover families arriving in the city under various talent programmes. The one-off cash allowance of HK$20,000 (US$2,550) had been distributed to 48,984 applicants as of the end of June, with HK$979 million handed out in total. The scheme was unveiled in Chief Executive John Lee Ka-chiu's 2023 policy address and currently requires the child to be born in Hong Kong between October 25, 2023, and October 24, 2026, to receive the handout. At least one parent must be a permanent resident at the time of application. Official statistics showed that the number of births in Hong Kong plunged from 37,000 in 2021 to 32,500 in 2022, before bouncing back to 33,200 in 2023 and 36,700 last year.
South China Morning Post
3 hours ago
- South China Morning Post
It's time to align Hong Kong's trading days with the mainland's
Money never sleeps in Hong Kong, except during some public holidays. The city is known for having many official days off. Often stock trading stops while other markets, including the one in mainland China, continue on their merry way of making money. In recent years, however, the city's stock exchange has been enhancing its services during traditional non-trading days. The next step, hopefully, will be to align holiday trading on Stock Connect with the mainland. Hong Kong's stock market is already dominated by Chinese companies, which account for around 80 per cent of its capitalisation. Since 2022, a large number of futures and options can be traded during holidays. Currency futures and options were included in March last year. The Hong Kong exchange has also moved to enhance the trading calendar for the Stock Connect programme, on both the northbound and southbound routes, to allow investors to trade on all days when both the mainland and Hong Kong markets are open. The Stock Connect, which links stock trading in Hong Kong with Shanghai and Shenzhen, enables a cross-border, two-way investing flow. It has offered more opportunities in Hong Kong for mainland investors and easier mainland access for international investors. Last year, the northbound and southbound average daily turnover was 150 billion yuan (US$20.7 billion) and HK$48.2 billion (US$6.2 billion), respectively, accounting for around 6 per cent and 18 per cent of the total turnover of the mainland and Hong Kong markets. The path forward is clear. More local holidays, though not all, can be open for trading. Christian holidays such as Easter and Christmas can be included since they are normal working days on the mainland. Additional trading days on the calendar can ease market disruptions caused by a mismatch in holidays, which has frustrated fund managers on both sides of the border.
South China Morning Post
10 hours ago
- South China Morning Post
How can you protect yourself if Hong Kong has a chikungunya fever outbreak?
Hong Kong has confirmed its first imported case of chikungunya fever since 2019, involving a 12-year-old boy, with health authorities urging residents to step up vigilance against the mosquito-borne disease. Should residents worry about a local outbreak? What protective measures should be taken? The Post breaks down the details for you. 1. What happened to the boy? The head of the communicable disease branch of the Centre for Health Protection, Dr Albert Au Ka-wing, said the boy lived in Kwun Tong and was diagnosed with the disease after returning from mainland China. He travelled with his mother to Foshan's Shunde district, where an outbreak is ongoing, from July 17 to 30 and reported being bitten by mosquitoes while outside. He developed a fever, rash and joint pain on Thursday and was confirmed to be infected on Saturday morning after being admitted to hospital. The disease is transmitted through bites from the Asian tiger mosquito. Photo: zb/dpa 2. What are the symptoms? Is it fatal? Chikungunya fever's symptoms are similar to those of dengue fever and include fever, rashes and joint pain, particularly in the hands and feet. A key difference is that chikungunya fever is generally milder than dengue, which can lead to more severe conditions like haemorrhagic fever.
